Local complement activation in inflammatory bowel disease

1991 ◽  
Vol 10 (3-4) ◽  
pp. 485-492 ◽  
Author(s):  
Trond S. Halstensen ◽  
Per Brandtzaeg
Keyword(s):  
Inflammatory Bowel Disease ◽  
Complement Activation ◽  
Bowel Disease ◽  
Inflammatory Bowel

scholarly journals C4Bgene influences intestinal microbiota through complement activation in patients with paediatric-onset inflammatory bowel disease

2017 ◽  
Vol 190 (3) ◽  
pp. 394-405 ◽  
Author(s):  
E. Nissilä ◽  
K. Korpela ◽  
A. I. Lokki ◽  
R. Paakkanen ◽  
S. Jokiranta ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Intestinal Microbiota ◽  
Complement Activation ◽  
Bowel Disease ◽  
Inflammatory Bowel

Association of C4B copy number variation and serum complement activation in vitro in patients with pediatric–onset inflammatory bowel disease

Immunobiology ◽  
2016 ◽  
Vol 221 (10) ◽  
pp. 1143
Author(s):  
Eija Nissilä ◽  
Riitta Paakkanen ◽  
Marja-Liisa Lokki ◽  
Sakari Jokiranta ◽  
Willem de Vos ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Copy Number Variation ◽  
Complement Activation ◽  
Bowel Disease ◽  
Copy Number ◽  
Serum Complement ◽  
Number Variation ◽  
Inflammatory Bowel ◽  
Pediatric Onset

scholarly journals P075 Epithelial Toll-like receptor 3-dependent synthesis of complement factor B and local complement activation in inflammatory bowel disease

2014 ◽  
Vol 8 ◽  
pp. S93-S94
Author(s):  
A.E. Østvik ◽  
A.v.B. Granlund ◽  
B.I. Gustafsson ◽  
S.H. Torp ◽  
T. Espevik ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Complement Activation ◽  
Bowel Disease ◽  
Complement Factor ◽  
Toll Like Receptor ◽  
Factor B ◽  
Complement Factor B ◽  
Inflammatory Bowel

scholarly journals Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease

2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Ramy M. Hanna ◽  
Noah Merin ◽  
Richard M. Burwick ◽  
Lama Abdelnour ◽  
Umut Selamet ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Hemolytic Uremic Syndrome ◽  
Lupus Erythematosus ◽  
Complement Activation ◽  
Bowel Disease ◽  
Atypical Hemolytic Uremic Syndrome ◽  
Kidney Injury ◽  
Uremic Syndrome ◽  
Inflammatory Bowel ◽  
Case Presentations

Abstract Background Atypical hemolytic uremic syndrome is a rare group of disorders that have in common underlying complement amplifying conditions. These conditions can accelerate complement activation that results in a positive feedback cycle. The known triggers for complement activation can be diverse and include, infection, autoimmune disease, and malignancy. Recent reports suggest that certain autoimmune and rheumatological triggers of complement activation may result in atypical hemolytic uremic syndrome that does not resolve despite treating the underlying disorder. Specifically, patients with systemic lupus erythematosus and microangiopathic hemolysis may not respond to treatment of their underlying rheumatological trigger but responded to complement blockade. Case presentations We report two patients with inflammatory bowel disease complicated by development of atypical hemolytic uremic syndrome. In both cases, patients were on treatment for inflammatory bowel disease, that was not well controlled/flaring at the time. The first patient is a male who developed Crohn’s disease and microangiopathic hemolysis at age 5 and was treated with eculizumab successfully. Discontinuation of the medication led to multiple relapses, and the patient currently is being treated with eculizumab and has normal hematological and stable renal parameters. The second patient is a 49-year-old female with Ulcerative Colitis treated with 6-Mercaptopurine. She developed acute kidney injury and microangiopathic hemolysis. Prompt diagnosis and treatment with eculizumab resulted in the recovery of kidney injury along with a complete hematological response. Conclusions These two cases are the fifth and sixth patients to be published in the literature with atypical hemolytic uremic syndrome and inflammatory bowel disease treated with complement blockade. This confirms that C5 complement blockade is effective in treating complement mediated thrombotic microangiopathy/atypical hemolytic uremic syndrome when it is triggered in patients with inflammatory bowel disease.

scholarly journals Mucosal Toll-like Receptor 3-dependent Synthesis of Complement Factor B and Systemic Complement Activation in Inflammatory Bowel Disease

2014 ◽  
pp. 1 ◽  
Author(s):  
Ann E. Østvik ◽  
Atle vB Granlund ◽  
Bjørn I. Gustafsson ◽  
Sverre H. Torp ◽  
Terje Espevik ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Complement Activation ◽  
Bowel Disease ◽  
Complement Factor ◽  
Toll Like Receptor ◽  
Factor B ◽  
Complement Factor B ◽  
Inflammatory Bowel

Disease severity predicts bone loss: A longitudinal study in inflammatory bowel disease patients

2001 ◽  
Vol 120 (5) ◽  
pp. A628-A628
Author(s):  
S HENDERSON ◽  
S DHALIWAL ◽  
N HOFFMAN ◽  
R PRINCE
Keyword(s):  
Inflammatory Bowel Disease ◽  
Longitudinal Study ◽  
Bone Loss ◽  
Disease Severity ◽  
Bowel Disease ◽  
Inflammatory Bowel

Low bone mineral density in association with increased bone resorbtion in patient with inflammatory bowel disease at diagnosis

2001 ◽  
Vol 120 (5) ◽  
pp. A628-A628
Author(s):  
T WONG ◽  
D SMITH ◽  
D SIMPSON ◽  
A COAKLEY ◽  
C MONIZ ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Inflammatory Bowel Disease ◽  
Bone Mineral ◽  
Bowel Disease ◽  
Mineral Density ◽  
Low Bone Mineral Density ◽  
Inflammatory Bowel

6-Mercaptopurine metaboline profile is optimized by azathioprine formulation and non-use of 5-aminosalicylic acid angents in patients with inflammatory bowel disease

2001 ◽  
Vol 120 (5) ◽  
pp. A625-A625 ◽  
Author(s):  
T STEVENS ◽  
J ACHKAR ◽  
A BRZEZINSKI ◽  
D SEIDNER ◽  
B LASHNER
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Aminosalicylic Acid ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document